FINEARTS试验中非奈利酮是否改善健康状况?对心衰患者报告结局分析的批判性再评估
该文批判性审视心衰试验中患者报告健康状况(KCCQ)的分析方法,指出均值差和阈值变化分析存在统计假设违背、MCID变异大、应答者分析敏感等问题。以FINEARTS试验为例,非奈利酮降低心衰住院风险18%,但KCCQ变化无法解释且临床可疑,仅<2%患者可能有 modest 获益。
要点
- KCCQ均值差分析依赖常被违背的统计假设,阈值变化分析中5点阈值并非普遍适用。
- KCCQ的MCID多数在10-20分,受患者特征、合并症和试验设计影响。
- FINEARTS试验中非奈利酮降低心衰住院风险18%,但KCCQ变化无法解释且临床可疑。
核心结论
- 当前KCCQ分析方法存在重大方法和分析局限性,可能导致对治疗效果的误判。
- FINEARTS试验中非奈利酮对KCCQ的影响无法解释且临床可疑,仅<2%随机患者可能有 modest 获益。
研究设计与样本
- 本文为对患者报告健康状况分析方法的批判性再评估,以FINEARTS试验为例进行讨论。
主要发现
- KCCQ均值差分析基于常被违背的统计假设。
- KCCQ的MCID多数在10-20分,随患者特征、合并症和试验设计变化。
- 应答者分析对两组方差差异高度敏感,且无法考虑KCCQ变化的稳定性。
- 将NNT应用于KCCQ评分进一步降低可解释性。
- FINEARTS试验中非奈利酮降低心衰住院风险18%,但KCCQ变化无法解释且临床可疑,仅<2%随机患者可能有 modest 获益。
关键数值与推荐
- KCCQ的MCID多数在10-20分。
- FINEARTS试验中非奈利酮降低心衰住院风险18%。
临床怎么用
- 临床医生应了解KCCQ分析的方法学局限,避免仅凭KCCQ变化做出临床决策。
局限性
- 本文为方法学批判性再评估,未提供新的试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patient-reported health status is an important assessment of patients with heart failure, but current approaches have substantial methodological and analytical limitations. Changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) are commonly presented as a measure of the effect of drugs and devices, most often as the between-group difference in population means or as the odds of showing threshold changes of 5, 10, 15, and 20 points. However, the presentation of mean differences is based on statistical assumptions that are routinely violated in most trials. The presentation of threshold changes is based on the belief that a within-patient change in KCCQ of 5 points represents a significant treatment difference across diverse populations and trial settings, but the minimal clinically meaningful difference varies substantially depending on patient characteristics, comorbidities, and trial duration and design, with most values for minimally clinically important difference for KCCQ ranging from 10 to 20 points. Furthermore, the assessment of between-group differences is highly distorted by the assignment of a large proportion of randomized patients with very good health status as having substantially improved even if they showed no change after treatment. Any responder analysis is highly sensitive to differences in variance between the 2 treatment groups and cannot account for the stability of changes in the KCCQ score. The imposition of number-to-treat presentations onto KCCQ scores further compounds the lack of interpretability of reported changes. It is therefore not surprising that trials have reported substantial discrepancies between the effect of treatment on KCCQ and on the risk of hospitalizations for heart failure. In the FINEARTS (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure) trial, finerenone produced an 18% reduction in the risk of hospitalizations for heart failure but yielded uninterpretable and clinically questionable changes in KCCQ, with the small possibility of a modest benefit in <2% of randomized patients. Most physicians are unaware of the critically important methodological concerns summarized in the current paper, and, therefore, may make clinical decisions that hinge on unwarranted impressions of the effects of an intervention on health status.
引用
- Butler, Usman, Harrell, et al. Did Finerenone Improve Health Status in the FINEARTS Trial?: A Critical Reevaluation of the Analysis of Patient-Reported Outcomes in Heart Failure. J Am Coll Cardiol. 2025. PMID: 39814478. doi:10.1016/j.jacc.2024.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。